RaQualia PharmaTSE:4579 -2.70%57 Days Payable is 34.17 as of Mar. 2026, which is 55% below its 10-year median of 75.33. GuruFocus rates TSE:4579 with a GF Score™ of 57/100 and a GF Value™ of 円961.31 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 699 Biotechnology companies, RaQualia Pharma ranks worse than 60.8% on this metric.
The historical rank and industry rank for RaQualia Pharma's Days Payable or its related term are showing as below:
TSE:4579'
s Days Payable Range Over the Past 10 Years
Min: 8.1 Med: 75.33 Max: 386.92
Current: 65.7
During the past 13 years, RaQualia Pharma's highest Days Payable was 386.92. The lowest was 8.10. And the median was 75.33.
TSE:4579's Days Payable is ranked worse than 60.8% of 699
companies
in the Biotechnology industry
Industry Median: 112.84
vs TSE:4579: 65.70
RaQualia Pharma's Days Payable
increased
from Dec. 2024 (0.00) to Mar. 2026 (34.17).
It may suggest that RaQualia Pharmadelayed paying its suppliers.
RaQualia Pharma Days Payable Related Terms
RaQualia Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, RaQualia Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
RaQualia Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a Days Payable of 34.17 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RaQualia Pharma and its competitors. This is 55% below median its historical median of 75.33. Over the past decade, RaQualia Pharma's Days Payable has ranged from 8.10 to 386.92. According to the industry distribution chart, RaQualia Pharma ranks #425 out of 699 companies in the Biotechnology industry, placing it in the top 60.8%.
Is RaQualia Pharma's Days Payable too high?
RaQualia Pharma's current Days Payable of 34.17 is 55% below median its 10-year median of 75.33. Over the past 10 years, this metric has ranged from a low of 8.10 to a high of 386.92. The Biotechnology industry median Days Payable is 112.84. RaQualia Pharma's value of 34.17 is 69.7% below this industry median. Based on the distribution chart, RaQualia Pharma ranks #425 out of 699 companies in the Biotechnology industry, which is below the industry midpoint. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #425 out of 699 companies for Days Payable. This places RaQualia Pharma in the lower half of its industry. The industry median Days Payable is 112.84. RaQualia Pharma's value of 34.17 is 69.7% below this benchmark. Historically, RaQualia Pharma's own Days Payable has ranged from 8.10 to 386.92 over the past decade. While the company's 10-year median is 75.33 vs. the industry median of 112.84, RaQualia Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaQualia Pharma's current Days Payable of 34.17 is 69.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current Days Payable is 34.17, which is 55% below median its own 10-year median of 75.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current Days Payable is 34.17, which is 55% below median its 10-year median of 75.33 and 69.7% below the Biotechnology industry median of 112.84. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Days Payable is 34.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued.
The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31.
GuruFocus considers RaQualia Pharma to be Significantly Undervalued.
Key valuation signals for TSE:4579:
Days Payable: 34.17 (55% below median its 10-year median of 75.33)
GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
Industry Position: 69.7% below the Biotechnology median (#425 of 699)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score
Get the complete analysis for TSE:4579
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
